Clinical-stage biopharmaceutical company Adocia (Euronext Paris:ADOC) announced on Tuesday that it has filed patent applications for stable combinations of GLP-1 and amylin analogs for the treatment of obesity and diabetes using its BioChaperone platform.
These combinations, such as CagriSema (cagrilintide and semaglutide), can be administered using standard injection devices, offering convenience and flexibility for patients.
Adocia's innovation addresses the challenge of combining different hormones for more effective obesity treatments. By overcoming compatibility issues, Adocia's BioChaperone platform enables the production of stable formulations that can be administered using existing injection devices. This could significantly improve the accessibility and convenience of these treatments.
Adocia is also researching new peptide combinations for obesity treatment and exploring partnerships to advance these innovations.
GSK PLC announces acceptance of NDA for gepotidacin by US FDA
Anixa Biosciences administers second dose of CAR-T therapy to individual patient
RevOpsis Therapeutics receives SBIR grant of over USD1.8m
AtomVie Global Radiopharma partners with Radiopharm Ventures
Lipella granted patent for innovative drug delivery technology
Adocia patents stable hormone combinations for obesity and diabetes
Accord BioPharma's IMULDOSA receives US FDA approval to treat chronic inflammatory conditions
RedHill Biopharma's opaganib selected for Ebola treatment development by BARDA
Quest Diagnostics acquires OhioHealth lab assets
Exelixis and Merck collaborate on clinical development of zanzalintinib
BD launches automated reagent kit to streamline single-cell discovery studies
Transgene's Phase II trial of TG4001 falls short of primary objective
GSK reports positive Phase III results for depemokimab in chronic rhinosinusitis with nasal polyps
SkylineDx reveals new data from the MERLIN_001 prospective US multi-centre trial